Michele O'connell
About Michele O'connell
Michele O'Connell is a Rare Disease Sales Specialist currently employed at Aimmune Therapeutics since 2020. She has over a decade of experience in sales within the pharmaceutical industry, having previously worked for Allergan and Forest Laboratories.
Work at Aimmune Therapeutics
Michele O'Connell has been employed at Aimmune Therapeutics since 2020, serving as a Rare Disease Sales Specialist. In this role, she focuses on promoting therapies for rare diseases, leveraging her extensive background in sales to drive awareness and adoption of specialized treatments. Her work is based in New Jersey, where she engages with healthcare professionals to facilitate access to innovative solutions for patients.
Previous Experience at Allergan
Prior to her current role, Michele O'Connell worked at Allergan for six years as a Specialty Sales Representative from 2014 to 2020. In this position, she operated in Southern New Jersey, where she developed relationships with healthcare providers and promoted specialty pharmaceuticals. Her tenure at Allergan contributed to her expertise in the pharmaceutical sales industry.
Sales Roles at Forest Laboratories and Actavis
Michele O'Connell has a decade of experience in sales and sales management at Forest Laboratories, now part of Allergan, from 2001 to 2011. During this time, she worked across New Jersey, Delaware, and Maryland. Following this, she spent three years at Actavis plc, also in specialty sales, from 2011 to 2014 in Southern New Jersey. These roles provided her with a solid foundation in pharmaceutical sales and customer relationship management.
Education and Expertise
Michele O'Connell earned her Bachelor's degree in Communication and Media Studies from Rowan University. Her educational background has equipped her with skills in effective communication, which are essential in her sales roles within the pharmaceutical industry. This academic foundation supports her ability to convey complex information to healthcare professionals and stakeholders.